What they were paid
Contineum Therapeutics Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $51,500 | $0 | $45,035 | $0 | $96,535 |
| FY2024 | $41,169 | — | $390,182 | — | $431,351 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Contineum Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001628280-26-028881, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Contineum Therapeutics pays directors a $40,000 cash retainer.
Committees
FY2025 · as the proxy prints themAudit · Nominating/Governance
The rest of the Contineum Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Carmine N. Stengone | Director | $0 |
| Diego Miralles | Director | $254,156 |
| Evert Schimmelpennink | Chair of the Board | $120,035 |
| Olivia Ware | Independent Director | $94,035 |
| Sarah Boyce | Independent Director | $93,035 |
| Todd Brady | Independent Director | $102,535 |
| Troy Ignelzi | Independent Director | $100,035 |
The full Contineum Therapeutics compensation record
free company briefThis page is one director within Contineum Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat